About

John M. Inadomi is a professor in the Department of Internal Medicine at the University of Utah Health, where he holds the Jon M. Huntsman Presidential Chair and serves as the Chair of the Department of Internal Medicine. He is a gastroenterologist with expertise in comparative effectiveness research, focusing on techniques to decrease mortality from esophageal adenocarcinoma and interventions to increase adherence to colorectal cancer screening tests. Dr. Inadomi received his undergraduate degree in mechanical engineering from MIT and his M.D. from the University of California, San Francisco, where he also completed his residency in internal medicine and fellowship in gastroenterology. He has been on the faculty of several institutions, including the University of New Mexico, the University of Michigan, UCSF, and the University of Washington, where he served as Division Head of Gastroenterology for 10 years. He is an associate editor of Gastroenterology, the President-Elect of the American Gastroenterological Association, and was set to become the President of the AGA in 2021. His research includes evaluating new endoscopic techniques, managing Barrett's esophagus, and addressing disparities in gastrointestinal cancer screening and outcomes.

Research topics

• Medicine
• Internal medicine
• Mathematics
• Demography
• Medical physics
• Environmental health
• Oncology
• Virology
• Intensive care medicine

Selected publications

• Abstract 7603: Type-2 Diabetes, medications, and risk of multiple colorectal polyps: A colonoscopy-based study using natural language processing.

  Cancer Research · 2026-04-03

  article

  Abstract Introduction: Colorectal polyps are known precursors to colorectal cancer (CRC), and a higher polyp count is associated with an increased CRC risk. This study aimed to investigate the impact of type-2 diabetes (T2D) and its treatments on polyp count. Methods: We leveraged pathology reports from the University of Utah (UofU) Enterprise Data Warehouse (EDW) to develop a rule-based natural language processing pipeline, to extract polyp diagnoses and features (site, count) for 38,038 patients who underwent colonoscopy at the UofU Gastroenterology clinic from 2011-2020. We identified 6,556 patients with T2D via ICD codes and anti-diabetes medication prescriptions. Patient characteristics were extracted from the EDW, including age, sex, race, smoking, BMI, anti-inflammatory medication use, and active prescriptions for insulin, metformin, sulfonylureas, GLP-1 agonists, and DPP-4 inhibitors. Polyp count was categorized as none, one, or multiple. Adjusted odds ratios (OR) and 95% confidence intervals (CI) for polyp counts were calculated using multinomial logistic regression. Results: Patients were on average 56 years old, 84% White, 51% female, with a mean BMI of 30 kg/m2. 73% of patients with T2D used anti-diabetes medications. T2D alone was not associated with multiple polyps, but patients with T2D taking anti-diabetes medications had a lower risk of polyps overall, irrespective of polyp count. Insulin use was associated with an increased risk of one or multiple polyps [OR(95%CI)=1.29(1.08-1.54) and 1.40(1.18-1.66), respectively], compared to other medications. Metformin and GLP-1 agonists were both associated with a decreased risk of one [Metformin OR(95% CI)=0.71(0.59-0.85), GLP-1=0.79(0.64-0.99)] or multiple polyps [Metformin OR(95% CI)=0.71(0.52-0.73), GLP-1=0.63(0.51-0.77)], compared to patients taking medications other than metformin or GLP-1 agonists, respectively. Compared to patients taking no anti-diabetes medications, those on insulin, metformin, DPP-4 inhibitors, or sulfonylureas had an increased risk of at least one polyp, while patients taking GLP-1 agonists had a lower risk of multiple polyps [OR(95%CI)=0.81(0.63-1.03)]. DPP-4 inhibitors and sulfonylureas also had a lower risk of multiple polyps [OR(95%CI)=0.79(0.64-0.97) and 0.80(0.68, 0.96), respectively]. Conclusion: Overall, T2D alone was not associated with polyp count, but medication use modified this relationship. Insulin use was associated with increased risk, whereas the use of metformin, GLP-1 agonists, DPP-4 inhibitors, and sulfonylureas was associated with decreased risk of one or multiple polyps, compared to patients taking other anti-diabetes medications. These results highlight the potential role of T2D medication choice in altering colorectal polyp risk, underscoring the need for more research into underlying mechanisms to guide potential interventions. Citation Format: Jessica van Onselen, Ryzen Benson, Stephanie Richardson, Maci Winn, Candace Winterton, Svenja Pauleck, Ainhoa Gomez-Lumbreras, Polly A. Newcomb, Cornelia M. Ulrich, John Inadomi, Sheetal Hardikar. Type-2 Diabetes, medications, and risk of multiple colorectal polyps: A colonoscopy-based study using natural language processing [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 7603.

  PublisherDOI

• Mo1134 THE BOSS TRIAL WAS LIKELY UNDERPOWERED FOR ITS PRIMARY OUTCOME OF OVERALL MORTALITY REDUCTION: A MODELING STUDY

  Gastroenterology · 2026-05-01

  article
  PublisherDOI

• Mentorship in Gastroenterology – The Final Lesson

  Clinical Gastroenterology and Hepatology · 2026-03-09

  articleSenior author
  PublisherDOI

• Mo1134 THE BOSS TRIAL WAS LIKELY UNDERPOWERED FOR ITS PRIMARY OUTCOME OF OVERALL MORTALITY REDUCTION: A MODELING STUDY

  Gastrointestinal Endoscopy · 2026-05-01

  article
  PublisherDOI

• Interventions for Increasing Colorectal Cancer Screening Uptake: A Systematic Review and Network Meta-Analysis

  Gastroenterology · 2026-04-01

  articleSenior author
  PublisherDOI

• Tul330 DIABETES AND ANTIHYPERGLYCEMIC MEDICATIONS ARE DIFFERENTIALLY ASSOCIATED WITH ADENOMATOUS AND SERRATED COLORECTAL POLYPS: A COLONOSCOPY-BASED STUDY

  Gastroenterology · 2026-05-01

  article
  PublisherDOI

• The Best Screening Test Is the One That Gets Followed-Up On

  Gastroenterology · 2026-02-01

  articleOpen access

  Background Drug-drug interactions (DDIs) can harm patients admitted to the intensive care unit (ICU).Yet, clinical decision support systems (CDSSs) aimed at helping physicians prevent DDIs are plagued by low-yield alerts, causing alert fatigue and compromising patient safety.The aim of this multicentre study was to evaluate the effect of tailoring potential DDI alerts to the ICU setting on the frequency of administered high-risk drug combinations.Methods We implemented a cluster randomised stepped-wedge trial in nine ICUs in the Netherlands.Five ICUs already used potential DDI alerts.Patients aged 18 years or older admitted to the ICU with at least two drugs administered were included.Our intervention was an adapted CDSS, only providing alerts for potential DDIs considered as high risk.The intervention was delivered at the ICU level and targeted physicians.We hypothesised that showing only relevant alerts would improve CDSS effectiveness and lead to a decreased number of administered high-risk drug combinations.The order in which the intervention was implemented in the ICUs was randomised by an independent researcher.The primary outcome was the number of administered high-risk drug combinations per 1000 drug administrations per patient and was assessed in all included patients.This trial was registered in the Netherlands Trial Register (identifier NL6762) on Nov 26, 2018, and is now closed.Findings In total, 10 423 patients admitted to the ICU between Sept 1, 2018, and Sept 1, 2019, were assessed and 9887 patients were included.The mean number of administered high-risk drug combinations per 1000 drug administrations per patient was 262 (SD 534) in the intervention group (n=5534), compared with 356 (650) in the control group (n=4353).Tailoring potential DDI alerts to the ICU led to a 12% decrease (95% CI 5-18%; p=00008) in the number of administered high-risk drug combinations per 1000 drug administrations per patient, after adjusting for clustering and prognostic factors.Interpretation This cluster randomised stepped-wedge trial showed that tailoring potential DDI alerts to the ICU setting significantly reduced the number of administered high-risk drug combinations.Our list of high-risk drug combinations can be used in other ICUs, and our strategy of tailoring alerts based on clinical relevance could be applied to other clinical settings.

  PublisherDOI

• Tul330 DIABETES AND ANTIHYPERGLYCEMIC MEDICATIONS ARE DIFFERENTIALLY ASSOCIATED WITH ADENOMATOUS AND SERRATED COLORECTAL POLYPS: A COLONOSCOPY-BASED STUDY

  Gastrointestinal Endoscopy · 2026-05-01

  article
  PublisherDOI

• Can artificial intelligence fulfill its potential to improve health and reduce costs?

  Endoscopy · 2026-05-20

  article1st authorCorresponding
  PublisherDOI

• Social needs screening in hepatology clinic: a qualitative study of patient experience

  BMC Gastroenterology · 2026-04-07

  articleOpen access
  PublisherDOI

Recent grants

• NIH Grant R01CA106773

  NIH · $1.4M · 2011

• Esophageal Cancer from Cells to Population: A Multiscale Approach

  NIH · $3.3M · 2013–2019

• Improving Gastrointestinal Disease Outcomes in Vulnerable Populations

  NIH · $1.8M · 2008–2022

• Controlling Esophageal Cancer: A Collaborative Modeling Approach

  NIH · $5.9M · 2018–2022

• University of Washington GI Training Grant

  NIH · $5.2M · 1996–2023

Frequent coauthors

• Gary W. Falk

  209 shared

• Jacques Van Dam

  200 shared

• Joel H. Rubenstein

  University of Michigan–Ann Arbor

  145 shared

• David A. Lieberman

  Oregon Health & Science University

  139 shared

• Janusz Jankowski

  University College London

  130 shared

• Krish Ragunath

  125 shared

• Eamonn M.M. Quigley

  Cornell University

  122 shared

• Kenneth T. Wang

  Fuller Theological Seminary

  119 shared

Education

• B.S., Mechanical Engineering

  Massachusetts Institute of Technology (M.I.T.)

• M.D.

  University of California, San Francisco (UCSF)

Awards & honors

• Jon M. Huntsman Presidential Chair